ClinicalTrials.gg
RecruitingNCT06338865Updated May 10, 2024

Short Title: Standard vs. Lower Pressure Pneumoperitoneum

An interventional study of Carbon dioxide and Bupivacaine in Laparoscopic Surgery, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pneumoperitoneum with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Pneumoperitoneum · United States.

Planned enrollment
Largest of 14
294 · median 70
Started
2024
the only one that year
No phase
14 of 17
4 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Cedars-Sinai Medical Center

Among the 17 studies in Pneumoperitoneum with a site in United States, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 14 with no phase, and was the 14th registered.

Pneumoperitoneum

133 studies on the registry are indexed under Pneumoperitoneum; 28 are open to participants now.

Browse Pneumoperitoneum studies →

Open to participants now

4 of the 17 studies in Pneumoperitoneum with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Pneumoperitoneum studies recruiting now, 8 (62%) set no upper age limit and 3 (23%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pneumoperitoneum with a site in United States, or all of them as a file.
02

Study summary

This study aims to investigate the effect of varying insufflation pressures on post-operative pain and adequacy of surgical field visualization among patients undergoing laparoscopic surgery with a minimally invasive gynecologic surgeon.

Read the detailed description

This will be a single-center, single-blinded randomized controlled trial evaluating the impact of lower pressure pneumoperitoneum on post-operative pain and surgical field visualization among patients undergoing laparoscopic gynecologic surgery. The investigators hypothesize that lower insufflation pressures will decrease post-operative pain in the immediate post-operative period without compromising surgical field visualization. The study will include 3 groups corresponding to varying insufflation pressures: 15mmHg (standard), 12mmHg and 10mmHg. Participants will be 1:1:1 allocated to the 15mmHg, 12mmHg or 10mmHg groups (parallel design) by block randomization.

Given inherent differences in how pneumoperitoneum is maintained during conventional versus robotic-assisted laparoscopic surgery, the investigators will be enrolling patients in two separate arms depending on their planned procedure:

  1. Standard vs. Lower Pressure Pneumoperitoneum in Conventional Laparoscopic Gynecologic Surgery
  2. Standard vs. Lower Pressure Pneumoperitoneum in Robotic-Assisted Laparoscopic Gynecologic Surgery.

The methodology for the two arms will be otherwise identical.

03

Conditions studied

  • Laparoscopic Surgery

Keywords

  • laparoscopic surgery
  • insufflation
  • pneumoperitoneum
  • gynecologic surgery
  • postoperative pain
  • robotic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • 18 years of age or older
  • Undergoing laparoscopic surgery at Cedars-Sinai Medical Center with a surgeon in the Minimally Invasive Gynecologic Surgery division.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Urgent/non-scheduled surgery
  • Scheduled for planned or possible concomitant non-gynecologic surgery (e.g., urologic or colorectal procedure)
  • Baseline opioid use
  • Allergy or intolerance to bupivacaine (or amide class of anesthetics), oxycodone, acetaminophen, or ibuprofen
  • Planned post-operative admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
294 participants (estimated)

Study arms

  • Active comparator
    15mmHg (Conventional Laparoscopic Arm)

    Standard Pressure, Conventional Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

  • Experimental
    12mmHg (Conventional Laparoscopic Arm)

    Lower Pressure, Conventional Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

  • Experimental
    10mmHg (Conventional Laparoscopic Arm)

    Lowest Pressure, Conventional Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

  • Active comparator
    15mmHg (Robotic-Assisted Laparoscopic Arm)

    Standard Pressure, Robotic-Assisted Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

  • Experimental
    12mmHg (Robotic-Assisted Laparoscopic Arm)

    Lower Pressure, Robotic-Assisted Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

  • Experimental
    10mmHg (Robotic-Assisted Laparoscopic Arm)

    Lowest Pressure, Robotic-Assisted Laparoscopic Arm

    Other: Carbon dioxide · Drug: Bupivacaine · Drug: Oxycodone

Interventions

  • OtherCarbon dioxide

    Gas used for insufflation pressure

  • Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).

  • All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.

06

What researchers measure

Primary outcomes

  1. Maximum documented pain score in post-anesthesia care unit (PACU) (numerical rating scale, 0-10)

    The numerical rating scale is a pain screening tool that is routinely used to assess pain severity in the postoperative setting using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: Postoperatively, before discharge from PACU (postoperative day 0)

Secondary outcomes

  1. First reported pain score in PACU (numerical rating scale, 0-10)

    The numerical rating scale is a pain screening tool that is routinely used to assess pain severity in the postoperative setting using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: Immediately upon arrival to PACU (postoperative day 0)

  2. Last reported pain score in PACU prior to discharge (numerical rating scale, 0-10)

    The numerical rating scale is a pain screening tool that is routinely used to assess pain severity in the postoperative setting using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: Immediately prior to discharge from PACU (postoperative day 0)

  3. Inpatient morphine milligram equivalents

    Daily total of opioid medications administered on the day of surgery

    Time frame: Day of surgery (postoperative day 0)

  4. Total number of 5mg oxycodone pills taken in the 2 weeks following discharge

    Time frame: Assessed at postoperative day 14

  5. Need for insufflation pressure increase intra-operatively due to inadequate visualization

    Time frame: Intraoperative

  6. Operative time

    Time frame: Intraoperative

  7. Estimated blood loss

    Time frame: Intraoperative

  8. Intraoperative complications

    Time frame: Intraoperative

  9. Conversion to laparotomy

    Time frame: Intraoperative

  10. Postoperative length of stay

    From arrival to PACU to discharge home

    Time frame: Postoperatively, before discharge from PACU (postoperative day 0)

  11. Surgeon-reported adequacy of assigned insufflation pressure

    Surgeons will rate their agreement with the following statement on a 5-point Likert scale (from strongly disagree to strongly agree): "The assigned insufflation pressure was adequate for this procedure"

    Time frame: Immediately following surgery

  12. Need for adjustment of insufflation pressure

    In a post-op questionnaire, surgeons will indicate whether the insufflation pressure was adjusted at any point during the procedure (yes/no).

    Time frame: Intraoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2027, 35 months after the start.

Of 40 non-industry interventional studies with no phase under Pneumoperitoneum, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 35 months is above that.

Counting every sponsor, half of 40 studies reached it within 8 months; a quarter within 4 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 1, 2024
StartActual
May 3, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338865
Responsible party
Matthew Siedhoff, MD MSCR (Vice Chair for Gynecology, Cedars-Sinai Medical Center) — Principal investigator
First posted
Apr 1, 2024
Start date
May 3, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 10, 2024

Study contacts

Rebecca Schneyer, MD
Contact
rebecca.schneyer@cshs.org
914-391-2604
Rebekah Odum, BSN
Contact
rebekah.odum@cshs.org
Matthew Siedhoff, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Oxycodone

Start the discussion